Last reviewed · How we verify
Helios Research Center — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| prilocaine 1% | prilocaine 1% | marketed | Local anesthetic (amide) | Voltage-gated sodium channels | Anesthesia |
Therapeutic area mix
- Anesthesia · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Beijing Tiantan Hospital · 1 shared drug class
- Bozyaka Training and Research Hospital · 1 shared drug class
- Centre Hospitalier Departemental Vendee · 1 shared drug class
- Centre Hospitalier Universitaire de Nīmes · 1 shared drug class
- Chiang Mai University · 1 shared drug class
- China Medical University, China · 1 shared drug class
- ASST Gaetano Pini-CTO · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Helios Research Center:
- Helios Research Center pipeline updates — RSS
- Helios Research Center pipeline updates — Atom
- Helios Research Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Helios Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/helios-research-center. Accessed 2026-05-16.